Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 2
2007 6
2008 4
2009 6
2010 7
2011 10
2012 10
2013 14
2014 7
2015 8
2016 8
2017 1
2018 5
2019 6
2020 9
2021 6
2022 6
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Anaplastic large-cell lymphoma.
Inghirami G, Pileri SA; European T-Cell Lymphoma Study Group. Inghirami G, et al. Semin Diagn Pathol. 2011 Aug;28(3):190-201. doi: 10.1053/j.semdp.2011.03.002. Semin Diagn Pathol. 2011. PMID: 21850985 Review.
Editorial: Genomics of Lymphoproliferative Disease.
Maura F, Agnelli L, Bortoluzzi S. Maura F, et al. Among authors: agnelli l. Front Oncol. 2021 Mar 17;11:660016. doi: 10.3389/fonc.2021.660016. eCollection 2021. Front Oncol. 2021. PMID: 33816317 Free PMC article. No abstract available.
Long Non-Coding RNAs in Multiple Myeloma.
Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C, Neri A. Nobili L, et al. Among authors: agnelli l. Genes (Basel). 2018 Feb 1;9(2):69. doi: 10.3390/genes9020069. Genes (Basel). 2018. PMID: 29389884 Free PMC article. Review.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. Lo Russo G, et al. Among authors: agnelli l. J Immunother Cancer. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. J Immunother Cancer. 2023. PMID: 37286305 Free PMC article. Clinical Trial.
Bioinformatics Pipeline to Analyze lncRNA Arrays.
Todoerti K, Ronchetti D, Manzoni M, Taiana E, Neri A, Agnelli L. Todoerti K, et al. Among authors: agnelli l. Methods Mol Biol. 2021;2348:45-53. doi: 10.1007/978-1-0716-1581-2_3. Methods Mol Biol. 2021. PMID: 34160798
MicroRNAs in the pathobiology of multiple myeloma.
Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. Lionetti M, et al. Among authors: agnelli l. Curr Cancer Drug Targets. 2012 Sep;12(7):823-37. doi: 10.2174/156800912802429274. Curr Cancer Drug Targets. 2012. PMID: 22671930 Review.
Anaplastic lymphoma kinase in human cancer.
Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G; European T-Cell Lymphoma Study Group. Barreca A, et al. J Mol Endocrinol. 2011 Jul 4;47(1):R11-23. doi: 10.1530/JME-11-0004. Print 2011 Aug. J Mol Endocrinol. 2011. PMID: 21502284 Review.
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Vingiani A, et al. Among authors: agnelli l. JCO Precis Oncol. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067. JCO Precis Oncol. 2023. PMID: 37487147 Free PMC article.
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L, Vingiani A, Garuti A, Vernieri C, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G. Ferrando L, et al. Among authors: agnelli l. PLoS Genet. 2023 Jan 3;19(1):e1010563. doi: 10.1371/journal.pgen.1010563. eCollection 2023 Jan. PLoS Genet. 2023. PMID: 36595552 Free PMC article.
114 results